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OBJECTIVES The investigators undertook a systematic, comprehensive analysis of the therapeutic response
and clinical outcomes of reperfusion therapy for acute ST-segment elevation myocardial
infarction (STEMI) in 5,470 patients from the Assessment of the Safety and Efficacy of a
New Thrombolytic Regimen (ASSENT)-3 trial.
BACKGROUND Prompt effective reperfusion therapy for acute STEMI may attenuate major myocardial
necrosis.
METHODS We prospectively collected sequential electrocardiographs and clinical data. Aborted myo-
cardial infarction (MI) was defined as maximal creatine kinase 2 upper limit of normal
coupled with typical evolutionary electrocardiographic changes.
RESULTS Of the patients, 727 (13.3%) had an aborted MI, with the highest frequency (25%) occurring
in patients treated 1 h after symptom onset. As compared with MI patients, patients with
aborted MI more often had complete ST-segment resolution at 60 min (56.3% vs. 30.2%, p
 0.001) and 180 min (61.5% vs. 53%, p  0.001); they also had smaller infarct sizes based
on QRS score at discharge (2.37 vs. 4.62, p 0 .001). Mortality in aborted MI patients
compared with those who had true MI was 3.9% versus 4.6% at 30-day and 7.0% versus 7.4%
at 1-year. The baseline-adjusted mortality was significantly lower in patients with aborted MI
(odds ratio [OR] 0.76, 95% confidence interval [CI] 0.63 to 0.92, p  0.005 for 30-day and
OR 0.70, 95% CI 0.50 to 0.98, p  0.035 for one year). A very low-risk subset was identified
with 70% ST-segment resolution at 60 min whose 30-day and 1-year mortality was 1.0%
and 2.7%, respectively, compared with 5.9% and 9.3% in aborted MI patients with 70%
ST-segment resolution at 60 min (all p  0.002).
CONCLUSIONS Prompt fibrinolytic treatment improved the likelihood of aborted MI. The subgroup with
complete 60-min ST-segment resolution had the best clinical outcomes. (J Am Coll
Cardiol 2004;44:38–43) © 2004 by the American College of Cardiology Foundationa
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dhe outcome of patients with ST-segment elevation myo-
ardial infarction (STEMI) is strongly influenced by the
ime from symptom onset to successful reperfusion. Some
atients who receive prompt reperfusion are known to avoid
yocardial necrosis. This population of “aborted myocardial
nfarction” patients was first characterized by Lamfers et al.
1) in 42 patients who had improved clinical outcomes.
iven the increased emphasis on early therapy and im-
roved outcomes (2), we undertook the current study to
omprehensively analyze aborted MI patients from the
ssessment of the Safety and Efficacy of a New Thrombo-
ytic Regimen (ASSENT)-3 trial population. This trial was
prospective, randomized study evaluating three different
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oehringer-Ingelheim (Germany), Genentech (South San Francisco, California),
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Manuscript received January 8, 2004; revised manuscript received March 4, 2004,tccepted March 11, 2004.ntithrombotic strategies in conjunction with tenecteplase
n STEMI (3). This large population provided a unique
pportunity to evaluate patients with aborted myocardial
nfarction (MI) and undertake a systematic analysis of their
herapeutic response and outcome. Specifically, we asked: 1)
hat is the frequency of patients escaping myocardial
ecrosis (i.e., aborted MI)? 2) Do such individuals have
articular identifying features? 3) What are their clinical
utcomes?
ETHODS
he specific entry criteria of the ASSENT-3 trial have been
efined previously (3); briefly, patients were 18 years of age
r older, with symptom onset 6 h before randomization,
nd ST-segment elevation of at least 0.1 mV in two or more
imb leads or at least 0.2 mV in two or more contiguous
recordial leads or presumed new left bundle branch block.
lasma samples for creatine kinase (CK) and the CK-MB
raction were collected on admission and subsequently
uring the hospitalization according to local hospital prac-
ice. For confirmation of the entry acute MI as well as any
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July 7, 2004:38–43 Aborted Myocardial Infarctionecurrent ischemia or reinfarction during hospitalization,
eak CK/CK-MB and/or troponin I/T were used and
ecorded in the case report form as multiples exceeding the
pper limits of normal.
Standard 12-lead electrocardiograms (ECGs) were col-
ected at baseline, at 60 and 180 min after treatment, and at
ischarge. The ST-segment measurements were evaluated
entrally at the ECG core laboratories (Canadian VIGOUR
entre, University of Alberta, Edmonton, Canadian Heart
esearch Centre, Toronto, Canada, and Duke Clinical
esearch Institute, Durham, North Carolina) without
nowledge of treatment or outcome. ST-segment elevation
as measured manually at the J-point using a hand-held
aliper. The sum of ST-segment elevation in leads V1 to V6,
, and aVL was added to the sum of ST-segment depression
n leads II, III, and aVF for anterior MI. For inferior MI,
he sum of ST-segment elevation in leads II, III, and aVF
and I, aVL, V5, and V6, if present) were added to the sum
f ST-segment depression in leads V1 to V4. The ST-
Abbreviations and Acronyms
ASSENT-3  Assessment of the Safety and Efficacy of a
New Thrombolytic Regimen-3 trial
CABG  coronary artery bypass graft
CI  confidence interval
CK-MB  creatine kinase-MB fraction
ECG  electrocardiogram/electrocardiographic
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial
infarction
Table 1. Baseline Characteristics
n
Age (median yrs) 60
Age  75 yrs
Female
Hypertension
Diabetes
Previous MI
Prior CABG
Prior PCI
Current smoker
Chronic aspirin
Anterior MI
Killip class  I
Systolic blood pressure (median mm Hg) 132
HR (median beats/min) 74
Time to treatment (median h)
Symptom to presentation 2.5
Door to needle 0.27
Symptom to tenecteplase 2.78
 ST-segment deviation on admission (mm) 12
Left bundle branch block
Data are percentages except where specified. *p  0.05 for ma
CABG  coronary artery bypass grafting; HR  heartintervention.egment resolution at 60 min and 180 min was classified
ccording to the Schroder et al. method (4): complete (i.e.,
esolution of the initial ST-segment elevation 70%),
artial (i.e., ST-segment resolution 70% to 30%), and
one (i.e., ST-segment resolution30%). QRS scores were
alculated (5) on both baseline and discharge ECGs.
For this study, sequential ECGs of patients with maximal
K 2 upper normal were reanalyzed by three indepen-
ent reviewers to examine the evolution in QRS and ST-T
aves. Aborted MI was defined as maximal CK2 upper
imit of normal combined with typical evolutionary ECG
hanges. Patients who had neither a rise in enzyme levels
or evolutionary changes in the QRS and ST-T waves were
eparately classified as masquerading MI.
Descriptive statistics were summarized as medians with
5th and 75th percentiles for continuous variables, and the
ann-Whitney U test was used. For categorical variables,
ata were summarized in percentages, the Fisher exact test
as used for dichotomous variables, and the chi-square test
as used for the rest of the categorical variables. The crude
ortality rate was adjusted for key baseline clinical charac-
eristics (Table 1) using multivariate logistic regression. The
tatistical analysis was performed using SPSS Version 11.0
SPSS Inc., Chicago, Illinois).
ESULTS
n Figure 1, the derivation of our patient population is
resented. There were 6,095 patients enrolled in the
SSENT-3 trial. Patients excluded from our study con-
isted of 100 patients (1.6%) who died in the first 24 h, 509
atients (8.4%) without available maximal CK data, and 16
atients (0.3%) without an available baseline ECG. The
I
,632
Aborted MI
n  727
Masquerading MI
n  111
69) 62 (53–71)† 64 (55–72)*
9 12.9 18.9*
0 30.5† 24.3
2 46.5† 55.0*
4 20.6† 24.3*
6 21.9† 28.8*
4 5.1† 9.9*
4 10.5† 7.3
2 42.3† 33.9*
8 26.5† 38.7*
9 35.8 33.3*
7 12.0 19.8*
–150) 130 (116–150) 130 (118–145)
85) 74 (62–86) 74 (61–86)
7–3.63) 2.2 (1.48–3.18)† 2.91 (2.0–4.48)*
7–0.40) 0.25 (0.17–0.38) 0.30 (0.20–0.42)
0–3.97) 2.51 (1.75–3.57)† 3.17 (2.24–4.93)*
8) 8 (6–12)† 5 (3–7)*
1 0.8 14.4*
ding MI vs. true MI; †p  0.05 for aborted MI vs. true MI.
I  myocardial infarction; PCI  percutaneous coronaryM
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Aborted Myocardial Infarction July 7, 2004:38–43emaining 5,470 patients formed the study population, of
hom 838 (15.3%) patients had maximal CK 2 upper
imit of normal. When this group was analyzed, 111 (2%)
atients had no evolutionary ECG changes and were
haracterized as “masquerading MI.” Thus, a final cohort of
27 (13.3%) patients fulfilled the criteria of “aborted MI.”
Demographic and clinical characteristics are shown in
able 1. Compared with true MI, patients with aborted MI
ere more likely to be older, female, and have a history of
ypertension and diabetes. They also had a higher frequency
f previous MI, coronary artery bypass grafting (CABG),
ercutaneous coronary intervention (PCI), and chronic
spirin use and were less likely to be current smokers.
borted MI patients had lower sum of ST-segment devia-
ion on their ECG at the time of admission. Time from
ymptom onset to treatment was shorter for aborted MI
igure 1. Identification of aborted myocardial infarction (MI) and mas-
uerading MI from Assessment of the Safety and Efficacy of a New
hrombolytic Regimen (ASSENT)-3 trial. CK creatine kinase; ECG
lectrocardiogram; ULN  upper limit of normal.Figure 2. Rate of aborted myocardial infarction (MI) according to time fatients largely because of their faster presentation to the
ospital. The occurrence of aborted MI according to hours
rom symptom onset to treatment is shown in Figure 2,
here aborted MI was highest within the first hour (25%)
ut decreased thereafter (by 3 h, it was 10%).
Patients with aborted MI were more likely to have a
on-urgent PCI or CABG (urgent or non-urgent) and less
ikely to develop in-hospital complications such as conges-
ive heart failure and major arrhythmias (Table 2). Although
able 2. Clinical Management and Outcomes
MI
n  4,632
Aborted
MI
n  727
Masquerading
MI
n  111
ABP 2.3 2.3 0.9
ngiogram 45.9 55.5 41.4
rgent PCI 11.9 10.6 1.8‡
on-urgent PCI 17.7 23.7† 9.9‡
rgent CABG 1.6 2.8† 0
on-urgent CABG 2.7 5.1† 1.8
HF 3.1 0.8† 0.9
hock 2.8 2.2 1.8
n-hospital major bleed
(exc ICH)
2.9 4.5† 6.3‡
CH up to discharge 0.9 0.6 0.9
ajor arrhythmias 9.2 6.1† 2.7‡
n-hospital reinfarction 2.9 3.0 0.9
n-hospital refractory
ischemia
4.7 4.0 2.7
ischarge Killip class I 95.6 95.8 98.1
ortality at 30 days 4.6 3.9 3.6
0-day composite end
point*
11.3 9.9 6.3
ortality at 1 yr 7.4 7.0 8.3
ata are percentages except where specified. *30 days death, in-hospital reinfarction,
efractory ischemia; †p  0.05 for aborted MI vs. true MI; ‡p  0.05 for
asquerading MI vs. true MI.
CHF  chronic heart failure; IABP  intra-aortic balloon pump; ICH 
ntracerebral hemorrhage; other abbreviations as in Table 1.rom symptom onset to treatment. p  0.001 for trend comparison.
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July 7, 2004:38–43 Aborted Myocardial Infarctionhere were no differences in the crude mortality rates at 30
ays and 1 year between the aborted MI and true MI
atients, mortality was significantly lower in aborted MI
atients as compared with true MI (odds ratio [OR] 0.76,
5% confidence interval [CI] 0.63 to 0.92, p  0.005 for
0-day mortality; OR 0.70, 95% CI 0.50 to 0.98, p 0.035
or one year) after adjusting for baseline characteristics.
here were no differences in treatment assignments be-
ween aborted MI and true MI groups.
The extent of ST-segment resolution according to the
I type is presented in Figure 3. The ST-segment resolu-
ion of 70% occurred with a higher frequency in the
borted MI population at 60 min (56.3% vs. 30.2%, p 
.001) and 180 min (61.5% vs. 53%, p  0.001). By 180
in, there were a similar proportion of patients (14% vs.
4.8%) in both groups with 30% ST-segment resolution.
igure 3. ST-segment resolution at 60 and 180 min. p  0.001 for trend
n that category. Dark gray bars30% ST-segment resolution; light gra
esolution. MI  myocardial infarction.
igure 4. Clinical outcomes of aborted myocardial infarction (MI) pati
omparison between groups. White bars  aborted MI with 70 ST-se
T-segment resolution at 60 min (n  239).aseline and discharge QRS scores (mean  SE) were 2.42
0.05 and 4.62 0.06 for the MI group (n 3,074); 1.80
0.11 and 2.37  0.12 for the aborted MI group (n 
92); and 1.27  0.24 and 1.58  0.27 for the masquer-
ding MI group (n  60).
In Figure 4, the effect of early ST-segment resolution on
he outcomes within the aborted MI population revealed a
tatistically significant difference in 30-day mortality (i.e.,
% in the subgroup with 70% ST-segment resolution at
0 min vs. 5.9% mortality in those with 70% ST-segment
esolution; p  0.002). This difference increased at one year
i.e., mortality was 2.7% vs. 9.3%, respectively; p  0.002)
nd remained statistically significant after adjusting for
aseline characteristics (OR 0.28, 95% CI 0.11 to 0.71, p 
.007 for aborted MI patients with complete ST-segment
esolution vs. those without). There were no significant
arison within each time point. Numbers represent percentage of patients
s 30% to 70% ST-segment resolution; white bars70% ST-segment
ccording to extent of 60-min ST-segment resolution. *p  0.002 for
t resolution at 60 min (n  300); gray bars  aborted MI with 70%comp
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Aborted Myocardial Infarction July 7, 2004:38–43ifferences in the frequency of angiography, urgent PCI
ischemia-driven PCI before hospital discharge), urgent
ABG, or non-urgent CABG in aborted MI patients with
70% or 70% ST-segment resolution at 60 min. How-
ver, there was a higher rate of non-urgent PCI in the
borted MI group, with70% ST-segment resolution at 60
in (30% vs.18.4% in the remaining aborted MI patients, p
0.003).
In the course of our analysis, we identified a group we
ave termed “masquerading MI” that presents without a rise
n enzyme levels or typical evolutionary ECG changes but
as several distinguishing features (Table 1). Specifically,
hen compared with patients with true MI, masquerading
I patients were older with more comorbidity (hyperten-
ion, diabetes, previous MI, and CABG) and a higher
requency of Killip class I on admission. They also had a
onger time to treatment from symptom onset, mostly
ecause of a delayed presentation to hospital and a much
ower ST-segment deviation on baseline ECGs. Their
linical outcomes differed from MI patients in that they had
higher rate of in-hospital major bleeds (excluding intra-
erebral hemorrhage) and a lower rate of PCI (urgent or
on-urgent) and major arrhythmias.
Among the 509 patients without peak CK, we identified
he 463 patients with either CK-MB or cardiac troponins
vailable, and the remaining 46 patients did not have
nzyme data. The criteria (i.e., 2  the upper limit of
ormal of CK-MB or cardiac troponins) were used for
efining the aborted MI for these 463 patients. When these
atients were included in separate analyses, the aborted MI
ncidence remained nearly identical (i.e., 12.7% vs. 13.3%
ithout these patients), and the other characteristics and
linical outcomes of aborted MI patients also were similar.
The following diagnoses simulating STEMI were iden-
ified in the 111 “masquerading MI” patients: early repolar-
zation (n  26; 23.4%), left bundle branch block (n  16;
4.4%), right bundle branch block/ventricular tachycardia/
olff-Parkinson-White syndrome (n  3; 2.7%), pericar-
itis (n  5; 4.5%), previous MI with persistent ST-
egment elevation (n  15; 13.5%), normal ECG (n  4;
.6%), and nondiagnostic ST-T changes (n  42; 37.8%).
ISCUSSION
ur study of 727 patients with aborted MI is the largest and
ost comprehensive analysis to date, providing new insights
nto those STEMI patients treated with fibrinolysis who
scape myocardial necrosis as measured by an increase in
K. Specifically, we have identified the incidence of aborted
I by hour of treatment, evolution of ST segments, and
urther validated the protection from myocardial damage by
he change in QRS scores. Finally, we have identified two
ey patient subgroups; one with 70% ST-segment reso-
ution at 60 min and another with “masquerading” MI that
ave significant clinical implications.
The frequency of aborted MI in our study was 13.3%, and phe greatest occurred in those patients treated within 1 h of
ymptom onset, with a sharp drop off after 3 h. This pattern
losely parallels the concept of the “golden hour” as popu-
arized by Boersma et al. (2). Hence, our findings add
urther evidence to the growing body of data highlighting
he major benefit of early treatment on STEMI patients (6).
We also demonstrate that patients with aborted MI have
ifferent clinical features from true MI patients. Specifically,
hey are more likely to have had a previous diagnosis or
ntervention for coronary artery disease and are much more
ikely to present earlier to the hospital.
The ECG evolutionary changes in our study also provide
ew insights. Whereas the initial aborted MI study of
amfers et al. (1) limited ECG analysis to two observations
t baseline and 120 min, our study examined four sequential
ystematically acquired ECGs and demonstrated a high
arly frequency of ST-segment resolution at 60 min as
ompared with true MI patients. This difference became
ess evident at 180 min and was almost equalized by
ischarge, emphasizing the value of early reperfusion. This
tility of the 12-lead ECG reinforces the close correlation
oted between 60-min ECGs and with short-term mortal-
ty noted in previous studies (7). The QRS evaluation on
aseline and discharge provides further corroborative evi-
ence that MI abortion signals the preservation of the
yocardium (5,8–10). We also propose a new subclassifi-
ation of aborted MI patients (i.e., those with maximal CK
nzyme levels 2 upper limit of normal and 70%
T-segment resolution at 60 min). In this group, early
eperfusion is associated with minimal myocardial damage
nd an excellent one-year clinical prognosis. Because this
roup had a higher rate of mechanical coronary interven-
ion, we cannot exclude this care as a contributing factor to
heir better outcomes.
Finally, another key MI subset identified in our study was
masquerading MI,” or those who had neither an enzyme
ise nor ST-segment evolution. These 111 patients consti-
uted 2% of the ASSENT-3 trial patients with suspected
cute MI. Although such patients have been previously
dentified as an issue that merits consideration (11–13), they
ave been poorly characterized and continue to emerge as
nappropriate inclusions in clinical studies. These patients
resent with symptoms that are suggestive of STEMI but
epresent a diagnostic dilemma presumably reflected by a
onger time to treatment and less baseline ST-segment
levation versus patients with true MIs. Our data provide
linical clues that should raise suspicion among physicians
reating these patients (i.e., these patients are older and have
ore incidence of diabetes, comorbidity, and ECG con-
ounders).
Although modest in number, the masquerading MI
atients had a disproportionately higher bleeding rate and
ence are unnecessarily exposed to the risks of fibrinolytic
herapy without the anticipated benefits. We urge greater
urveillance to avoid the unnecessary inclusion of such
atients in future trials: They may benefit from additional
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July 7, 2004:38–43 Aborted Myocardial Infarctioniagnostic measures or mechanical intervention rather than
brinolysis because they have a higher frequency of Killip
lass I and worse one-year mortality despite the initial
bsence of true MI.
In the absence of a standard, various investigators have
sed different definitions for aborted MI, limiting the
efinition to CK-MB (14) or to this plus 50% ST-
egment resolution (1,15). In the current study, aborted MI
as defined as maximal CK 2 upper limit of normal
ith dynamic ECG changes. We do not have access to the
pecific times of enzyme measurements the ASSENT-3
rial protocol required for the confirmation of the presence
f MI through sequential enzymatic measurements. Al-
hough it is impossible to exclude a sampling bias, this
ppears unlikely given the similar frequency of aborted MI
n our study versus previous ones (1,14,15).
Our findings should prove useful for future STEMI
anagement and investigations by enhancing the ability to
xclude patients with masquerading MI. In conclusion, the
oncept of aborted MI appears a meaningful one related to
mproved clinical outcomes, lesser time to treatment data,
nd evolutionary ECG changes that are indicative of early
eperfusion and preservation of myocardium.
eprint requests and correspondence: Dr. Paul W. Armstrong,
niversity of Alberta, 2-51 Medical Sciences Building, Edmonton,
lberta T6G 2H7 Canada. E-mail: paul.Armstrong@ualberta.ca.
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